Active Immunotherapy of Breast Cancer Treatment
Abstract
Immunotherapy as a specific moleculer targeted therapy could modulate immune respons through cytotoxic CD8+ pathway so that generate anti-tumor activity on breast cancer. HER2/Neu is the one of tumor associated antigen which extensively studied to reduce cancer progression. CTLA-4 has important role in immune checkpoint blockade that it is used for studying breast cancer either in early or advanced level. In this review, we discussed principle of immunotherapy in tumor microenvironment and some kinds of active immunotherapies, which included cancer vaccination and immune checkpoint blockade. Majority of those immunotherapies are ongoing clinical trial. Hence, this becomes a promising new field in breast cancer therapies in a future and will ultimately change the current status of breast cancer therapies.
Full Text:
PDFReferences
World Health Organization. Latest Global Cancer Data: Cancer Burden Rises to 18.1 Million New Cases and 9.6 Million Cancer Deaths in 2018.; 2018. http://gco.iarc.fr/,.
World Health Organization. Indonesia Source GLOBOCAN 2018. Int Agency Res Cancer. 2019;256:1-2. http://gco.iarc.fr/.
Arafah ABR, Notobroto HB. FAKTOR YANG BERHUBUNGAN DENGAN PERILAKU IBU RUMAH TANGGA MELAKUKAN PEMERIKSAAN PAYUDARA SENDIRI (SADARI) Alvita Brilliana R. Arafah, Hari Basuki Notobroto. Ijph. 2017;12(August):143-153. doi:10.20473/ijph.v12i1.2017.143-153
Angahar LT. An Overview of Breast Cancer Epidemiology, Risk Factors, Pathophysiology, and Cancer Risks Reduction. MOJ Biol Med. 2017;1(4):92-96. doi:10.15406/mojbm.2017.01.00019
Altucci L. Breast Cancer Vaccines : New Insights. 2017;8(October):1-7. doi:10.3389/fendo.2017.00270
American Cancer Society. Breast Cancer: Treatment Guideline for Patients. Nccn. 2006;(September):6.
Cardoso F, Kyriakides S, Ohno S, et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(8):1194-1220. doi:10.1093/annonc/mdz173
Lin-Yu Yu , Jie Tang , Cong-Min Zhang, Wen-Jing Zeng , Han Yan M-PL and X-PC. Immunotherapy of breast cancer.pdf. Int J Environ Res Public Heal Rev. 2017;14(68):1-18. doi:10.3390/ijerph14010068
Sanchez K, Page D, Heather L. Immunotherapy in breast cancer: An overview of modern checkpoint blockade strategies and vaccines. Curr Probl Cancer. 2016. doi:10.1016/j.currproblcancer.2016.09.009
Abbas AK, Lichtman AH PS. Basic Immunology Functions and Disroders of the Immune System Fifth Edition.; 2016.
Criscitiello C. Tumor-associated antigens in breast cancer. Breast Care. 2012;7(4):262-266. doi:10.1159/000342164
Peethambaram PP, Melisko ME, Rinn KJ, et al. A phase I trial of immunotherapy with lapuleucel-T (APC8024) in patients with refractory metastatic tumors that express HER-2/neu. Clin Cancer Res. 2009;15(18):5937-5944. doi:10.1158/1078-0432.CCR-08-3282
Allahverdiyev A, Tari G, Bagirova M, Abamo ES. Current approaches in development of immunotherapeutic vaccines for breast cancer. J Breast Cancer. 2018;21(4):343-353. doi:10.4048/jbc.2018.21.e47
Schütz F, Marmé F, Domschke C, Sohn C, Von Au A. Immunooncology in Breast Cancer: Active and Passive Vaccination Strategies. Breast Care. 2018;13(1):22-26. doi:10.1159/000486330
Miles D, Roché H, et al. Phase III Multicenter Clinical Trial of the Sialyl‐TN (STn)‐Keyhole Limpet Hemocyanin (KLH) Vaccine for Metastatic Breast Cancer. Oncologist. 2011;16(8):1092-1100. doi:10.1634/theoncologist.2010-0307
Apostolopoulos V, Pietersz GA, Tsibanis A, et al. Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835]. Breast Cancer Res. 2006;8(3):1-11. doi:10.1186/bcr1505
Mohebtash M, Tsang KY, Madan RA, et al. A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer. Clin Cancer Res. 2011;17(22):7164-7173. doi:10.1158/1078-0432.CCR-11-0649
Yamaguchi R, Tanaka M, Yano A, et al. Tumor-infiltrating lymphocytes are important pathologic predictors for neoadjuvant chemotherapy in patients with breast cancer. Hum Pathol. 2012;43(10):1688-1694. doi:10.1016/j.humpath.2011.12.013
Denkert C, Loibl S, Noske A, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2010;28(1):105-113. doi:10.1200/JCO.2009.23.7370
Hu ZI, Ho AY, Mcarthur HL. Combined Radiotherapy and Immune Checkpoint Blockade Therapy for Breast Cancer. Int J Radiat Oncol • Biol • Phys. 2017. doi:10.1016/j.ijrobp.2017.05.029
Hargadon KM, Johnson CE, Williams CJ. International Immunopharmacology Immune checkpoint blockade therapy for cancer : An overview of FDA- approved immune checkpoint inhibitors. Int Immunopharmacol. 2018;62(May):29-39. doi:10.1016/j.intimp.2018.06.001
Sosman JA, Haanen JB, Gonzalez R, et al. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. 2010;363(8):711-723.
Vonderheide RH, Lorusso PM, Khalil M, et al. Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells. Clin Cancer Res. 2010;16(13):3485-3494. doi:10.1158/1078-0432.CCR-10-0505
Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252-264. doi:10.1038/nrc3239
Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28(19):3167-3175. doi:10.1200/JCO.2009.26.7609
DOI: https://doi.org/10.37905/jmhsj.v1i2.15357
Refbacks
- There are currently no refbacks.
Jambura Medical and Health Science Journal (JMHSJ) has been indexed by:
 |  |  |  |
| Editorial Office |
Medical Faculty Building, 1st Floor Jl. Jend. Sudirman No.6, Kota Gorontalo, Gorontalo, 96128, Indonesia.Whatsapp: +6285233215280 Email: jmhsj@ung.ac.id |
 |